• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of August 12

Article

The Center for Biosimilars® recaps the top stories for the week of August 12, 2019.

Transcript

Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 12, 2019.

Number 5: Being presented with positively framed information on biosimilars is linked with greater willingness to accept a switch, says a recent study.

Number 4: New data from a phase 3 study in patients with rheumatoid arthritis show that Fresenius Kabi’s biosimilar adalimumab has similar safety to Humira.

Number 3: A retrospective analysis of prescription claims shows the importance of an oncology specialty pharmacy team in ensuring access to financial assistance.

Number 2: Authors of a new paper say it’s time to replace the totality of the evidence approach to biosimilars with a new paradigm.

Number 1: A judge ruled in favor of Amgen in a long-running patent litigation concerning Sandoz’s biosimilar etanercept, Erelzi.

Finally, last week, our e-newsletter asked whether you think that Celltrion’s proposed subcutaneous infliximab biosimilar could compete with brand-name adalimumab.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Recent Videos
Lakesha Farmer, PharmD
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Michael Kleinrock
Related Content
© 2024 MJH Life Sciences

All rights reserved.